Difference between revisions of "Paroxetine-maprotiline"
From Psychiatrienet
| Line 2: | Line 2: | ||
| from = paroxetine | | from = paroxetine | ||
| to = maprotiline | | to = maprotiline | ||
| − | | stop = | + | | stop = |
| − | + | * Decrease with about 25% of original dose every 3-4 days | |
| start = | | start = | ||
Caution is necessary. | Caution is necessary. | ||
| − | * '''Day | + | * '''Day 1:''' start administration of nortriptyline in a low dosage of 25 mg/day. |
| − | * '''Day | + | * '''Day Stop paroxetine:''' increase administration of nortriptyline to a dosage of 50 mg/day. |
| info = | | info = | ||
| − | + | * Paroxetine slows the metabolism of nortriptyline via CYP2D6. | |
| − | * Paroxetine slows the metabolism of | ||
}} | }} | ||
Revision as of 16:27, 30 June 2023
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from paroxetine to maprotiline.[1] [2]
Stop paroxetine - Decrease with about 25% of original dose every 3-4 days
Start maprotilineCaution is necessary.
- Day 1: start administration of nortriptyline in a low dosage of 25 mg/day.
- Day Stop paroxetine: increase administration of nortriptyline to a dosage of 50 mg/day.
More information- Paroxetine slows the metabolism of nortriptyline via CYP2D6.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
